High-Dose Oral Insulin Fails to Prevent Islet Autoimmunity: Primary Results from the POInT Randomized Trial
Posted inDiabetes & Endocrinology news Pediatrics

High-Dose Oral Insulin Fails to Prevent Islet Autoimmunity: Primary Results from the POInT Randomized Trial

The POInT trial demonstrated that high-dose daily oral insulin does not prevent islet autoantibodies in infants at high genetic risk for type 1 diabetes. Despite its safety, the primary endpoint was not met, though genotype-specific interactions suggest a need for more personalized prevention strategies.
Video Consultations for Insulin Pump-Treated Type 1 Diabetes: Non-Inferior Glycemic Control with Nuanced Patient Outcomes
Posted inDiabetes & Endocrinology Internal Medicine news

Video Consultations for Insulin Pump-Treated Type 1 Diabetes: Non-Inferior Glycemic Control with Nuanced Patient Outcomes

A 52-week RCT demonstrates that video consultations achieve comparable Time in Range (TiR) to physical visits for T1D patients on insulin pumps. While the intervention improved HbA1c and treatment satisfaction, it was associated with an inferior impact on patient quality of life.
Precision Hypertension Management: Haptoglobin Phenotype Predicts Cardiovascular Benefit from Intensive Blood Pressure Control in Type 2 Diabetes
Posted inCardiology Diabetes & Endocrinology news

Precision Hypertension Management: Haptoglobin Phenotype Predicts Cardiovascular Benefit from Intensive Blood Pressure Control in Type 2 Diabetes

A post-hoc analysis of the ACCORD trial reveals that intensive blood pressure control significantly reduces cardiovascular and stroke risk in haptoglobin 1 allele carriers, but not in those with the Hp2-2 phenotype, suggesting a genotype-driven approach to hypertension management in diabetes.
Reversing Prediabetes Halves 30-Year Risk of Cardiovascular Death and Heart Failure: New Insights from DPPOS and DaQing
Posted inCardiology Diabetes & Endocrinology news

Reversing Prediabetes Halves 30-Year Risk of Cardiovascular Death and Heart Failure: New Insights from DPPOS and DaQing

A landmark post-hoc analysis of the DPPOS and DaQing studies reveals that achieving prediabetes remission reduces the risk of cardiovascular death and heart failure hospitalization by approximately 50% over three decades, highlighting a profound legacy effect of early glycemic normalization.
RNAi Targeting of ANGPTL3 with Zodasiran Delivers Substantial LDL-C Lowering in Patients with Homozygous Familial Hypercholesterolaemia
Posted inCardiology Diabetes & Endocrinology news

RNAi Targeting of ANGPTL3 with Zodasiran Delivers Substantial LDL-C Lowering in Patients with Homozygous Familial Hypercholesterolaemia

The Phase 2 GATEWAY trial demonstrates that zodasiran, an RNAi therapeutic targeting ANGPTL3, significantly reduces LDL cholesterol in patients with homozygous familial hypercholesterolaemia (HoFH) by approximately 36-40%. The treatment was well-tolerated and showed sustained efficacy, offering a promising LDLR-independent therapeutic avenue for this high-risk population.
GLP-1 Receptor Agonists Associated with Significantly Lower Risk of Subarachnoid Hemorrhage in Patients with Intracranial Aneurysms
Posted inDiabetes & Endocrinology Neurology news

GLP-1 Receptor Agonists Associated with Significantly Lower Risk of Subarachnoid Hemorrhage in Patients with Intracranial Aneurysms

A large-scale retrospective cohort study reveals that GLP-1 receptor agonists reduce the risk of subarachnoid hemorrhage by 34% and all-cause mortality by 37% in patients with type 2 diabetes and intracranial aneurysms, suggesting a potent neuroprotective role for these metabolic agents.